Stevanato Group (STVN) Q4 FY25 earnings call

Stevanato Group concluded FY25 with robust performance driven by double-digit growth in its Biopharmaceutical and Diagnostic Solutions (BDS) segment, particularly from high-value solutions and GLP-1 related products. The company is strategically pivoting towards premium offerings, which is expanding margins, though the Engineering segment faces continued headwinds from slower order intake. Management is focused on capacity expansion for high-value products and expects sustained growth from biologics and GLP-1s, while actively managing operational improvements in new facilities.